@entity117 mono-therapy continuation does not result in more XXXX after knee arthroplasty.

@entity1 @entity548 @entity190 @entity117 @entity1503
PURPOSE: Current clinical practice guidelines sometimes still recommend stopping @entity117 five to seven days before knee arthroplasty surgery. Literature regarding multimodal blood management and continuation of anti-platelet therapy in this type of surgery is scant. The study hypothesis was that knee arthroplasty under low-dose @entity117 mono-therapy continuation does not cause more @entity190 than knee arthroplasty performed without @entity117 . @entity190 would be measured by haemoglobin (Hb) and haematocrit (HTC) levels drop at day 2 or day 4 for @entity1 who benefit from multimodal @entity548 control measures. METHODS: A database of all @entity1 undergoing knee arthroplasty between 2006 and 2014 was analysed. @entity1503 were collected. A retrospective comparison study analysed both groups in terms of @entity190 , by mean calculated @entity190 as haemoglobin or haematocrit drop between the preoperative Nadir value and the postoperative day 2 and 4 value. A group of 198 (44 UKA and 154 TKA) @entity1 underwent surgery without interrupting their @entity117 therapy for cardiovascular prevention. Mean (SD) age was 71 (8) and the mean (SD) BMI was 29 (5.5) kg/m(2). The control group consisted of 403 (102 UKA and 301 TKA) @entity1 who were not under @entity117 , or any other anti-platelet agent. Mean (SD) age was 65 (10) (p  <  0.05) and the mean (SD) BMI was 29 (5.0) kg/m(2) (n.s.). All @entity1 in the control group were randomly selected. RESULTS: There were no differences in terms of visible (early) or hidden (late) @entity190 as measured by Hb drop in between both groups. There is no difference in transfusion rates. CONCLUSIONS: Modern multimodal blood management provides sufficient @entity190 prevention during and after knee arthroplasty to allow physicians to continue low-dose @entity117 mono-therapy for cardiovascular prevention. LEVEL OF EVIDENCE: III.
